References
- Antila S, Huuskonen H, Nevalainen T, Kanerva H, Vanninen P, Lehtonen L. Site dependent bioavailability and metabolism of levosimendan in dogs. European Journal of Pharmaceutical Science 1999; 9: 85–91
- Antila S, Kivikko M, Lehtonen L, Eha J, Heikkilä A, Pohjanjousi P, Pentikäinen PJ. Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan. British Journal of Clinical Pharmacology 2004; 57: 412–415
- Babu SR, Lakshmi VM, Huang GP, Zenser TV, Davis BB. Glucuronide conjugates of 4-aminobiphenyl and its N-hydroxy metabolites. pH stability and synthesis by human and dog liver. Biochemistry and Pharmacology 1996; 51: 1679–1685
- Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola V-P, Mitrovic V, Abdalla M, Sandell E-P, Lehtonen L. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): A randomised double-blind trial. Lancet 2002; 360: 196–202
- Innes CA, Wagstaff AJ. Levosimendan. A review of its use in the management of acute decompensated heart failure. Drugs 2003; 63: 2651–2671
- Kivikko M, Antila S, Eha J, Lehtonen L, Pentikäinen PJ. Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. International Journal of Clinical Pharmacology and Therapy 2002a; 40: 465–471
- Kivikko M, Antila S, Eha J, Lehtonen L, Pentikäinen PJ. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure. Journal of Clinical Pharmacology 2002b; 42: 43–51
- Kivikko M, Lehtonen L, Colucci WS, on Behalf of the Study Investigators. Sustained hemodynamic effects of intravenous levosimendan. Circulation 2003; 107: 81–86
- Kristof E, Sziketi G, Papp Z, Bodi A, Facsko A, Kovacs L, Papp JG, Kranias EG, Edes I. Cardiac responses to calcium sensitizers and isoproterenol in intact guinea pig hearts. Effects on cyclic AMP levels, protein phosphorylation, myoplasmic calcium concentration and left ventricular function. Annals of the New York Academy of Sciences 1998; 853: 316–319
- Puttonen J, Laine T, Ramela M, Häkkinen S, Zhang W, Pradhan R, Pentikäinen P, Koskinen M. Pharmacokinetics and excretion balance of OR-1896, a metabolite of levosimendan, in healthy men. European Journal of Pharmaceutical Science 2007; 32: 271–277
- Sandell E-P, Häyhä M, Antila S, Heikkinen P, Ottoila P, Lehtonen L, Pentikäinen PJ. Pharmacokinetics of levosimendan in healthy volunteers and patients with congestive heart failure. Journal of Cardiovascular Pharmacology 1995; 26(Suppl. 1)S57–S62
- Sundberg S, Antila S, Scheinin H, Häyhä M, Virtanen M, Lehtonen L. Integrated pharmacokinetics and pharmacodynamics of the novel calcium sensitizer levosimendan as assessed by systolic time intervals. International Journal of Clinical Pharmacology and Therapy 1998; 36: 629–635
- Takahashi R, Talukder MAH, Endoh M. Effects of OR-1896, an active metabolite of levosimendan on contractile force and aequorin light transients in intact rabbit ventricular myocardium. Journal of Cardiovascular Pharmacology 2000a; 36: 118–125
- Takahashi R, Talukder MAH, Endoh M. Inotropic effects of OR-1896, an active metabolite of levosimendan, on canine ventricular myocardium. European Journal of Pharmacology 2000b; 400: 103–112